Clinical trial · no report yet · Phase 3
RASolve 301
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
- NCT06881784 ↗
- Recruiting
- Revolution Medicines, Inc.
- 3 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| X threads | 2 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 Versus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- NSCLC (Non-small Cell Lung Cancer); Non-Small Cell Lung Cancer; NSCLC; NSCLC (Non-small Cell Lung Carcinoma); NSCLC (Advanced Non-small Cell Lung Cancer)
- Interventions
- daraxonrasib; docetaxel
- Arms
- daraxonrasib · Experimental
- docetaxel · Active comparator
- Enrollment
- 590 (estimated)
- Primary outcomes
- Progression free survival (PFS) per Blinded Independent Central Review (BICR) in the RAS G12X-C population (i.e RAS G12X excluding G12C)
- Overall survival (OS) in the RAS G12X-C population
- Sponsor
- Revolution Medicines, Inc.
- Start
- May 6, 2025
- Primary completion
- Dec 1, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT06881784 · updated Sep 29, 2026